Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Share-based Compensation (2016 - 2025)

Pediatrix Medical (MD) has disclosed Share-based Compensation for 17 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 46.04% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.7 million, a 0.42% change, with the full-year FY2025 number at $11.7 million, down 1.42% from a year prior.
  • Share-based Compensation was $4.0 million for Q4 2025 at Pediatrix Medical, up from $3.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $5.8 million in Q2 2021 to a low of $1.4 million in Q3 2023.
  • A 5-year average of $3.5 million and a median of $3.6 million in 2021 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: tumbled 75.34% in 2021, then soared 195.68% in 2024.
  • Pediatrix Medical's Share-based Compensation stood at $4.0 million in 2021, then dropped by 19.75% to $3.2 million in 2022, then dropped by 6.29% to $3.0 million in 2023, then decreased by 9.42% to $2.7 million in 2024, then soared by 46.04% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Share-based Compensation are $4.0 million (Q4 2025), $3.4 million (Q3 2025), and $2.0 million (Q2 2025).